Photopharmacology is an emerging field that uses light to precisely control drug activity. This
strategy promises to improve drug specificity for reducing off-target effects. Proteolysis …

Conclusion The third-generation PROTAC strategy based on photopharmacology sheds the
light on future development of PROTACs. Optically controlled small-molecule PROTACs …

Proteolysis targeting chimeras, PROTACs, are emerging as a powerful strategy for exerting
exogenous control over protein levels, allowing small molecules to exploit the ubiquitin …

Off-tissue effects are persistent issues of modern inhibition-based therapies. By merging the
strategies of photopharmacology and small-molecule degraders, we introduce a novel …

Achieving tumor-specific protein loss remains a challenge in the delivery of proteolysis-
targeting chimeras (PROTACs) as cancer therapeutics. As a solution, Wang et al. recently …

By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome
system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit …

Proteolysis targeting chimeras (PROTACs) have emerged as a promising strategy for drug
discovery and exploring protein functions, offering a revolutionary therapeutic modality …

PROTACs (Proteolysis targeting chimeras) are chimeric molecules designed to induce
targeted protein degradation via the ubiquitin–proteasome system. These molecules …

Confining the protein degradation activity of proteolysis-targeting chimera (PROTAC) to
cancer lesions ensures precision treatment. However, it still remains challenging to precisely …

PROteolysis-TArgeting Chimeras (PROTACs) have been developed for targeting specific
protein destruction. Two recent studies in Science Advances by Liu et al. and Reynders et al …